mRNA-based tuberculosis vaccines BNT164a1 and BNT164b1 are immunogenic, well tolerated and efficacious in rodent models

Journal:
Nature Immunology
Published:
DOI:
10.1038/s41590-026-02545-z
Affiliations:
4
Authors:
11
Go to article
Institutions Authors Share
BioNTech, Germany
9.000000
 0.82
BioNTech US, United States of America (USA)
1.000000
 0.09
Translational Oncology (TRON), Germany
0.500000
 0.05
Helmholtz Institute for Translational Oncology Mainz (HI-TRON Mainz), Germany
0.500000
 0.05